Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gender differences in genital lichen sclerosus: data from a multicenter Italian study on 729 consecutive cases.
Virgili A, Borghi A, Cazzaniga S, Di Landro A, Naldi L, Minghetti S, Fierro MT, Verrone A, Caproni M, Micali G, Gaspari V, Papini M, Di Lernia V, Germi L, Girolomoni G, Belloni Fortina A, Cannavò SP, Bilenchi R, Corazza M; GLS Italian Study Group. Virgili A, et al. Among authors: verrone a. G Ital Dermatol Venereol. 2020 Apr;155(2):155-160. doi: 10.23736/S0392-0488.17.05819-9. Epub 2018 Jan 24. G Ital Dermatol Venereol. 2020. PMID: 29368855 Free article.
New insights into potential risk factors and associations in genital lichen sclerosus: Data from a multicentre Italian study on 729 consecutive cases.
Virgili A, Borghi A, Cazzaniga S, Di Landro A, Naldi L, Minghetti S, Verrone A, Stroppiana E, Caproni M, Nasca MR, D'Antuono A, Papini M, Di Lernia V, Corazza M; GLS Italian Study Group. Virgili A, et al. Among authors: verrone a. J Eur Acad Dermatol Venereol. 2017 Apr;31(4):699-704. doi: 10.1111/jdv.13867. Epub 2016 Aug 12. J Eur Acad Dermatol Venereol. 2017. PMID: 27515901
Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real-life experience in a tertiary referral centre.
Gallo G, Rostagno E, Siliquini N, Stroppiana E, Verrone A, Ortoncelli M, Quaglino P, Dapavo P, Ribero S. Gallo G, et al. Among authors: verrone a. Australas J Dermatol. 2021 Aug;62(3):e431-e432. doi: 10.1111/ajd.13632. Epub 2021 May 27. Australas J Dermatol. 2021. PMID: 34042171 No abstract available.
Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study.
Dapavo P, Siliquini N, Mastorino L, Avallone G, Merli M, Agostini A, Cariti C, Viola R, Stroppiana E, Verrone A, Ortoncelli M, Quaglino P, Ribero S. Dapavo P, et al. Among authors: verrone a. J Dermatolog Treat. 2022 Jun;33(4):2352-2357. doi: 10.1080/09546634.2021.1961998. Epub 2021 Aug 13. J Dermatolog Treat. 2022. PMID: 34315331 Free article.
Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement.
Mastorino L, Cariti C, Susca S, Sciamarrelli N, Borriello S, Ortoncelli M, Stroppiana E, Verrone A, Dapavo P, Quaglino P, Ribero S. Mastorino L, et al. Among authors: verrone a. Dermatol Ther. 2022 Nov;35(11):e15818. doi: 10.1111/dth.15818. Epub 2022 Sep 22. Dermatol Ther. 2022. PMID: 36097346 No abstract available.
Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients.
Mastorino L, Susca S, Cariti C, Sliquini N, Verrone A, Stroppiana E, Ortoncelli M, Dapavo P, Ribero S, Quaglino P. Mastorino L, et al. Among authors: verrone a. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1848-1853. doi: 10.1111/jdv.19135. Epub 2023 May 4. J Eur Acad Dermatol Venereol. 2023. PMID: 37113043
40 results